AstraZeneca ruling could mean more competition cases
The European Commission could be more likely to take action against IP owners for blocking competition, after a court today endorsed its AstraZeneca decision
The EU General Court broadly upheld the European Commissions 2005 decision that AstraZeneca had abused its dominant position by preventing the marketing of generic rivals to its blockbuster drug Losec.
It agreed with the Commission that the pharmaceutical...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.